0.136
-0.01 (-9.67%)
| Penutupan Terdahulu | 0.150 |
| Buka | 0.142 |
| Jumlah Dagangan | 56,824,261 |
| Purata Dagangan (3B) | 73,990,428 |
| Modal Pasaran | 35,914,492 |
| Harga / Jualan (P/S) | 0.510 |
| Harga / Buku (P/B) | 2.68 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Keuntungan | -38.91% |
| Margin Operasi (TTM) | -604.96% |
| EPS Cair (TTM) | -0.300 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 28.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 626.29% |
| Nisbah Semasa (MRQ) | 2.02 |
| Aliran Tunai Operasi (OCF TTM) | -107.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.50 M |
| Pulangan Atas Aset (ROA TTM) | -14.19% |
| Pulangan Atas Ekuiti (ROE TTM) | -275.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Adaptimmune Therapeutics plc | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.63% |
| % Dimiliki oleh Institusi | 44.16% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |